Patents Assigned to CV Therapeutics
  • Patent number: 6835563
    Abstract: The present invention relates to novel ABC1 polypeptides and nucleic acid molecules encoding the same. The invention also relates to recombinant vectors, host cells, and compositions comprising ABC1 polynucleotides, as well as to methods for producing ABC1 polypeptides. The invention also relates to antibodies that bind specifically to ABC1 polypeptides. In addition, the invention relates to methods for increasing cholesterol efflux as well as to methods for increasing ABC1 expression and activity. The present invention further relates to methods for identifying compounds that modulate the expression of ABC1 and methods for detecting the comparative level of ABC1 polypeptides and polynucleotides in a mammalian subject. The present invention also provides kits and compositions suitable for screening compounds to determine the ABC1 expression modulating activity of the compound, as well as kits and compositions suitable to determine whether a compound modulates ABC1-dependent cholesterol efflux.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: December 28, 2004
    Assignee: CV Therapeutics
    Inventors: Richard M. Lawn, David Wade, Michael Garvin, John F. Oram
  • Publication number: 20040064039
    Abstract: A myocardial imaging method that is accomplished by administering one or more adenosine A2A adenosine receptor agonist to a human undergoing myocardial imaging.
    Type: Application
    Filed: July 29, 2003
    Publication date: April 1, 2004
    Applicant: CV Therapeutics
    Inventor: Luiz Belardinelli
  • Patent number: 5869537
    Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: February 9, 1999
    Assignee: CV Therapeutics
    Inventors: George F. Schreiner, Louis G. Lange, III
  • Patent number: 5834487
    Abstract: This invention is a method for inhibiting cell proliferation using indanones.
    Type: Grant
    Filed: September 24, 1996
    Date of Patent: November 10, 1998
    Assignee: CV Therapeutics
    Inventors: Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Marek G. Nelson, Michael M. Wick
  • Patent number: 5789416
    Abstract: A substituted N.sup.6 -oxa, thia, thioxa and azacycloalkyl substituted adenosine derivative and a method for using the composition as an A.sub.1 heart adenosine receptor.
    Type: Grant
    Filed: August 27, 1996
    Date of Patent: August 4, 1998
    Assignee: CV Therapeutics
    Inventors: Robert T. Lum, Jurg R. Pfister, Steven R. Schow, Michael M. Wick, Marek G. Nelson, George F. Schreiner
  • Patent number: 5663450
    Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 2, 1997
    Assignee: CV Therapeutics
    Inventors: George F. Schreiner, Louis G. Lange, III
  • Patent number: 5429937
    Abstract: Intestinal cell endogenous heparin mediated absorption of cholesterol or fatty acids in mammals is inhibited through the oral administration of heparin, an active heparin subfraction or heparinase. Suppression of cholesterol esterase-mediated absorption in humans can be inhibited by soluble heparin by two mechanisms, i.e. displacement of the enzyme from the intestinal cell membrane and inhibition of enzymatic activity of the displaced enzyme.
    Type: Grant
    Filed: September 26, 1994
    Date of Patent: July 4, 1995
    Assignee: CV Therapeutics
    Inventors: Louis G. Lange, III, Curtis A. Spilburg, Paula M. Kinnunen